Novo Nordisk A/S is back on the hunt for deals to boost its obesity portfolio after losing US biotech Metsera Inc. in a bidding war with Pfizer Inc. late last year.
Author: Bloomberg News
Published at: 2026-01-13 22:07:00
Still want to read the full version? Full article
